Loading...
Orchid Pharma Community
NSEI:ORCHPHARMA Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
Community Investing Ideas
New Licensing Partnerships And Manufacturing Facilities Will Build Future Resilience
Key Takeaways Global expansion and licensing of innovative antibiotics strengthen Orchid's market position and support long-term revenue and margin growth. Enhanced manufacturing and product focus boost operational efficiency, margin resilience, and earnings stability amid industry consolidation and rising healthcare needs.Read more
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
₹960
12.3% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
38.4% p.a.
Profit Margin
10.9%
Future PE
27.97x
Share price in 2028
₹1.36k